Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Toth Financial Advisory Corp

Toth Financial Advisory Corp increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1,450.0% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,550 shares of the pharmaceutical company’s stock after purchasing an additional 1,450 shares during the period. Toth Financial Advisory Corp’s holdings in Vertex Pharmaceuticals were worth $721,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the stock. Trilogy Capital Inc. lifted its stake in shares of Vertex Pharmaceuticals by 26.1% during the third quarter. Trilogy Capital Inc. now owns 3,617 shares of the pharmaceutical company’s stock worth $1,682,000 after buying an additional 748 shares during the period. Koss Olinger Consulting LLC increased its holdings in shares of Vertex Pharmaceuticals by 4.1% in the third quarter. Koss Olinger Consulting LLC now owns 896 shares of the pharmaceutical company’s stock valued at $417,000 after purchasing an additional 35 shares during the period. Allspring Global Investments Holdings LLC raised its stake in shares of Vertex Pharmaceuticals by 18.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 236,326 shares of the pharmaceutical company’s stock worth $109,911,000 after purchasing an additional 37,399 shares during the last quarter. Cyndeo Wealth Partners LLC acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter worth about $600,000. Finally, Cedrus LLC increased its holdings in Vertex Pharmaceuticals by 18.3% in the 3rd quarter. Cedrus LLC now owns 774 shares of the pharmaceutical company’s stock worth $360,000 after buying an additional 120 shares during the period. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs sold 5,295 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $508.00, for a total value of $2,689,860.00. Following the sale, the director now owns 40,000 shares of the company’s stock, valued at $20,320,000. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, Chairman Jeffrey M. Leiden sold 3,784 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the sale, the chairman now owns 9,994 shares of the company’s stock, valued at approximately $4,987,006. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bruce I. Sachs sold 5,295 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $508.00, for a total value of $2,689,860.00. Following the completion of the transaction, the director now owns 40,000 shares of the company’s stock, valued at approximately $20,320,000. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 14,285 shares of company stock valued at $7,101,755. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Down 1.0 %

Shares of VRTX opened at $478.09 on Tuesday. Vertex Pharmaceuticals Incorporated has a 52-week low of $341.90 and a 52-week high of $510.64. The company has a market capitalization of $123.40 billion, a PE ratio of -235.51 and a beta of 0.40. The stock has a fifty day simple moving average of $475.48 and a two-hundred day simple moving average of $460.75. The company has a quick ratio of 2.26, a current ratio of 2.52 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing analysts’ consensus estimates of ($12.54) by ($0.29). The business had revenue of $2.65 billion during the quarter, compared to analysts’ expectations of $2.66 billion. Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. Vertex Pharmaceuticals’s revenue for the quarter was up 6.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.53 EPS. As a group, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post -2.11 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Canaccord Genuity Group increased their price objective on shares of Vertex Pharmaceuticals from $371.00 to $376.00 and gave the stock a “sell” rating in a research note on Wednesday, July 31st. UBS Group lifted their price objective on Vertex Pharmaceuticals from $477.00 to $562.00 and gave the company a “buy” rating in a research note on Thursday, October 17th. StockNews.com lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 5th. Truist Financial reissued a “buy” rating and issued a $550.00 price target (up from $508.00) on shares of Vertex Pharmaceuticals in a report on Monday, August 5th. Finally, TD Cowen raised their price objective on shares of Vertex Pharmaceuticals from $450.00 to $500.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Three analysts have rated the stock with a sell rating, ten have given a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $492.92.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.